EC Microbiology

Introduction: Mixed connective tissue disease (MCTD) is described as a connective tissue disorder characterized by the presence of high titers of a distinctive autoantibody, now called anti-U1 ribonucleoprotein (anti-RNP). It is assumed to be an overlap syndrome that includes clinical features of major diffuse connective tissue diseases. The overlap feature often take several years to appear clear enough to be establish the confident diagnosis of MCTD. Nowadays, there is a consensus to consider MCTD as a "distinct clinical entity".

Aim of the Work: The definition, criteria, clinical features, prognosis, and general principles of management will be presented in this review. In-depth details of management will not be presented.

Methodology: This article is a comprehensive review of medical literature regarding mixed connective tissue disease.

Conclusion: In most cases, MTCD cannot be differentiated from other classical DCTDs in the early stages as the simultaneous presence of overlap features seen in SLE, SSc, and polymyositis (PM) is rarely obvious. The overlapping features appear more evident sequentially over several years. Early symptoms are usually puffy fingers, easy fatigability, poorly defined myalgias, arthralgias, low-grade fever, and Raynaud phenomenon.

Mixed connective tissue disease has a relatively good prognosis and excellent response to glucocorticoids due to a low prevalence of serious renal disease and life-threatening neurologic problems. MCTD-associated mortality are substantial in various report, ranging from 16 to 28 percent at 10 to 12 years follow-up. The highest mortality rate is seen in patients with vascular involvement. The primary causes of death include progressive pulmonary hypertension (PAH) and its heart complications.

The management of MCTD is generally based upon the known effectiveness of specific therapies for similar diseases.

Keywords: Mixed Connective Tissue Disease; MCTD; Definition; Criteria; Prognosis; Management

1. Sharp GC., et al. “Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)”. The American Journal of Medicine 52 (1972): 148.
2. Bennett RM and O’Connell DJ. “Mixed connective tisssue disease: a clinicopathologic study of 20 cases”. Seminars in Arthritis and Rheumatism 10 (1980): 25.
3. Bennett RM. “Overlap syndromes”. In: Textbook of Rheumatology, 9^th, Firestein GS (Ed), WB Saunders Co, Philadelphia (2013).
4. Gunnarsson R., et al. “The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients”. Annals of the Rheumatic Diseases 70 (2011): 1047.
5. Maddison PJ. “Overlap syndromes and mixed connective tissue disease”. Current Opinion in Rheumatology 3 (1991): 995.
6. Mosca M., et al. “Undifferentiated connective tissue diseases (UCTD)”. Autoimmunity Reviews 6 (2006): 1.
7. Alarcón-Segovia D and Cardiel MH. “Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients”. The Journal of Rheumatology 16 (1989): 328.
8. Kahn MF and Appelboom T. “Syndrom de Sharp”. In: Les maladies systemiques, 3^rd, Kahn MF, Peltier AP, Meyer O, Piette JC (Eds), Flammarion, Paris (1991): 545.
9. Sen S., et al. “Cutaneous manifestations of mixed connective tissue disease: study from a tertiary care hospital in eastern India”. Indian Journal of Dermatology 59 (2014): 35.
10. Kitridou RC., et al. “Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study”. Seminars in Arthritis and Rheumatism 16 (1986): 135.
11. Bennett RM and O’Connell DJ. “The arthritis of mixed connective tissue disease”. Annals of the Rheumatic Diseases 37 (1978): 397.
12. Pope JE. “Other manifestations of mixed connective tissue disease”. Rheumatic Disease Clinics of North America 31 (2005): 519.
13. Mimura Y., et al. “Rheumatoid factor isotypes in mixed connective tissue disease”. Clinical Rheumatology 25 (2006): 572.
14. Takasaki Y., et al. “Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease”. Modern Rheumatology 14 (2004): 367.
15. Sullivan WD., et al. “A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease”. Medicine (Baltimore) 63 (1984): 92.
16. Bodolay E., et al. “Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD) ”. Rheumatology (Oxford) 44 (2005): 656.
17. Nishimaki T. “[Mixed connective tissue disease and overlap syndrome]”. Nihon Rinsho 57 (1999): 355.
18. Ungprasert P., et al. “Cardiac involvement in mixed connective tissue disease: a systematic review”. International Journal of Cardiology 171 (2014): 326.
19. Usuba FS., et al. “Sjögren’s syndrome: An underdiagnosed condition in mixed connective tissue disease”. Clinics (Sao Paulo) 69 (2014): 158.
20. Bennett RM., et al. “Neuropsychiatric problems in mixed connective tissue disease”. The American Journal of Medicine 65 (1978): 955.
21. Burdt MA., et al. “Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings”. Arthritis Rheum 42 (1999): 899.
22. Hojaili B and Barland P. “Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder”. Journal of Clinical Rheumatology 12 (2006): 145.
23. Nimelstein SH., et al. “Mixed connective tissue disease: a subsequent evaluation of the original 25 patients”. Medicine (Baltimore) 59 (1980): 239.
24. Hajas A., et al. “Clinical course, prognosis, and causes of death in mixed connective tissue disease”. The Journal of Rheumatology 40 (2013): 1134.
25. Gunnarsson R., et al. “Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study”. Annals of the Rheumatic Diseases 71 (2012): 1966.
26. Yoshida S. “Pulmonary arterial hypertension in connective tissue diseases”. Allergology International 60 (2011): 405.
27. Ueda Y., et al. “Successful treatment of acute right cardiac failure due to pulmonary thromboembolism in mixed connective tissue disease”. Japan Journal of Medicine 30 (1991): 568.
28. Sjogren RW. “Gastrointestinal motility disorders in scleroderma”. Arthritis and Rheumatology 37 (1994): 1265.
29. Ulmer A., et al. “Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease”. Journal of the American Academy of Dermatology 46 (2002): 123.